M
Melissa A. Ashlock
Researcher at Cystic Fibrosis Foundation
Publications - 15
Citations - 1757
Melissa A. Ashlock is an academic researcher from Cystic Fibrosis Foundation. The author has contributed to research in topics: Cystic fibrosis & Ivacaftor. The author has an hindex of 10, co-authored 15 publications receiving 1654 citations.
Papers
More filters
Journal ArticleDOI
Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation
Frank J. Accurso,Steven M. Rowe,John P. Clancy,Michael P. Boyle,Jordan M. Dunitz,Peter R. Durie,Scott D. Sagel,Douglas B. Hornick,Michael W. Konstan,Scott H. Donaldson,Richard B. Moss,Joseph M. Pilewski,Ronald C. Rubenstein,Ahmet Uluer,Moira L. Aitken,Steven D. Freedman,Lynn M. Rose,Nicole Mayer-Hamblett,Qunming Dong,Jiuhong Zha,Anne Stone,Eric R. Olson,Claudia L. Ordoñez,Preston W. Campbell,Melissa A. Ashlock,Bonnie W. Ramsey +25 more
TL;DR: This study showed that VX-770 was associated with within-subject improvements in CFTR and lung function and provides support for further studies of pharmacologic potentiation of CFTR as a means to treat cystic fibrosis.
Journal ArticleDOI
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation
John P. Clancy,Steven M. Rowe,Frank J. Accurso,Moira L. Aitken,Raouf S. Amin,Melissa A. Ashlock,Manfred Ballmann,Michael P. Boyle,Inez Bronsveld,Preston W. Campbell,Kris De Boeck,Scott H. Donaldson,Henry L. Dorkin,Jordan M. Dunitz,Peter R. Durie,Manu Jain,Anissa Leonard,Karen McCoy,Richard B. Moss,Joseph M. Pilewski,Daniel B. Rosenbluth,Ronald C. Rubenstein,Michael S. Schechter,Martyn Botfield,Claudia L. Ordoñez,George T. Spencer-Green,Laurent Vernillet,Steve Wisseh,Karl Yen,Michael W. Konstan +29 more
TL;DR: In this study, VX-809 had a similar adverse event profile to placebo for 28 days in F508del-CFTR homozygous patients, and demonstrated biological activity with positive impact on CFTR function in the sweat gland.
Journal ArticleDOI
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
F. Van Goor,B. Burton,Sabine Hadida,Peter Diederik Jan Grootenhuis,Eric R. Olson,Jeffrey J. Wine,Raymond A. Frizzell,Melissa A. Ashlock,Paul A. Negulescu +8 more
Journal ArticleDOI
Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data
Frank J. Accurso,Fredrick Van Goor,Jiuhong Zha,Anne Stone,Qunming Dong,Claudia L. Ordoñez,Steven M. Rowe,John P. Clancy,Michael W. Konstan,Heather Hoch,Sonya L. Heltshe,Sonya L. Heltshe,Bonnie W. Ramsey,Bonnie W. Ramsey,Preston W. Campbell,Melissa A. Ashlock +15 more
TL;DR: Analysis of changes in sweat chloride and NPD demonstrated that patients treated with ivacaftor achieved CFTR activity equivalent to approximately 35%–40% of normal, and Sweat chloride is useful in multicenter trials as a biomarker ofCFTR activity and to test the effect of CFTR potentiators.
Journal ArticleDOI
Therapeutics development for cystic fibrosis: a successful model for a multisystem genetic disease.
Melissa A. Ashlock,Eric R. Olson +1 more
TL;DR: A successful collaboration between a voluntary health organization and a pharmaceutical company, complemented by academic investigators and patients, has led to the clinical development of investigational drugs that restore function to defective CFTR protein in various tissues in CF patients.